Abstract | BACKGROUND: METHODS: RESULTS: After aliskiren treatment, there was a significant reduction in proteinuria in 4 weeks (1.76±0.95 to 1.03±0.69 g:g-Cr, p<0.0001), which remained at a low level throughout the treatment period. There was a significant difference in proteinuria between the aliskiren and placebo groups from 4 to 16 weeks after treatment (p<0.01 for all comparisons). After aliskiren treatment, there were modest but statistically significant reductions in eGFR (57.2±29.1 to 54.8±29.3 ml/min/1.73 m(2), pā=ā0.013) and diastolic blood pressure (72.6±12.3 to 66.2±11.2 mmHg, p<0.0001). None of the patient developed severe hyperkalemia (serum potassium ≥6.0 mmol/l) during the study period. CONCLUSIONS: TRIAL REGISTRATION: ClinicalTrials.gov NCT00870493.
|
Authors | Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, Chi-Bon Leung, Philip Kam-Tao Li |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 5
Pg. e62736
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 23675422
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amides
- Antihypertensive Agents
- Fumarates
- aliskiren
- Renin
|
Topics |
- Adult
- Amides
(administration & dosage, adverse effects, therapeutic use)
- Antihypertensive Agents
(administration & dosage, adverse effects, therapeutic use)
- Blood Pressure
(drug effects)
- Cross-Over Studies
- Female
- Fumarates
(administration & dosage, adverse effects, therapeutic use)
- Glomerular Filtration Rate
(drug effects)
- Glomerulonephritis, IGA
(drug therapy)
- Humans
- Hyperkalemia
(chemically induced)
- Male
- Middle Aged
- Proteinuria
(drug therapy)
- Renin
(antagonists & inhibitors, blood)
- Treatment Outcome
|